Search results for Dexamethasone - Clinical Trials Registry - ICH GCP

Example: Heart Attack

Search clinical trials for: Dexamethasone

Total 2593 results

NCT03117751

Recruiting

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
NCT05663866

Not yet recruiting

Premedication to Mitigate Amivantamab Infusion Related Reactions

Conditions: Carcinoma, Non-Small-Cell Lung
NCT03798678

Active, not recruiting

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
NCT04898920

Completed

Pre-emptive Dexamethasone in Hip Arthroplasty

Conditions: Postoperative Pain
NCT02385110

Completed

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Conditions: Leukemia
NCT05656521

Recruiting

101-PGC-005 for the Treatment of COVID-19

Conditions: COVID-19
NCT04925193

Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Conditions: Multiple Myeloma in Relapse
NCT04822337

Recruiting

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Conditions: Multiple Myeloma
NCT03959085

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
NCT02649790

Recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
NCT04113018

Active, not recruiting

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Conditions: Multiple Myeloma
NCT05432414

Recruiting

PVd Versus Vd in NDMM Patients With RI

Conditions: Multiple Myeloma
NCT04512235

Recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

Conditions: AL Amyloidosis
NCT04504825

Recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

Conditions: AL Amyloidosis
NCT04414475

Recruiting

A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma

Conditions: Multiple Myeloma, Refractory
NCT04161248

Recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Conditions: Lymphoma, B-Cell
NCT03773107

Active, not recruiting

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT03201965

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Conditions: Amyloidosis
NCT02883049

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With BCR-ABL1-Like Features, Central Nervous System Leukemia, Testicular Leukemia
NCT02343042

Active, not recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Conditions: Multiple Myeloma
NCT02101944

Active, not recruiting

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Anemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
NCT02003222

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
NCT00644228

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
NCT05572515

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Relapsed or Refractory Multiple Myeloma
NCT05552222

Recruiting

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma

Conditions: Multiple Myeloma